Cargando…

Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial

PURPOSE: Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee. PATIENTS AND METHODS: A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extra...

Descripción completa

Detalles Bibliográficos
Autores principales: Myers, Stephen P, Mulder, Ann M, Baker, Don G, Robinson, Shelley R, Rolfe, Margaret I, Brooks, Lyndon, Fitton, J Helen
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Dove Medical Press 2016
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887044/
https://www.ncbi.nlm.nih.gov/pubmed/27307702
http://dx.doi.org/10.2147/BTT.S95165
_version_ 1782434687287820288
author Myers, Stephen P
Mulder, Ann M
Baker, Don G
Robinson, Shelley R
Rolfe, Margaret I
Brooks, Lyndon
Fitton, J Helen
author_facet Myers, Stephen P
Mulder, Ann M
Baker, Don G
Robinson, Shelley R
Rolfe, Margaret I
Brooks, Lyndon
Fitton, J Helen
author_sort Myers, Stephen P
collection PubMed
description PURPOSE: Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee. PATIENTS AND METHODS: A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extract (85% fucoidan) over a 12-week period in a population (n=122) with mild-to-moderate OA of the hip and knee as measured by the validated instrument “Comprehensive Osteoarthritis Test.” Safety was measured by assessing cholesterol, liver function, renal function, and hematopoietic function, and closely monitoring adverse events. RESULT: Ninety-six participants completed the study. The reduction in symptoms of OA was not significantly different from the placebo response. There were no changes in the blood measurements that were of any clinical significance during the course of the study. CONCLUSION: The F. vesiculosus fucoidan extract was safe and well tolerated. At a dose of 300 mg, the extract showed no difference in reduction of OA symptoms from the placebo.
format Online
Article
Text
id pubmed-4887044
institution National Center for Biotechnology Information
language English
publishDate 2016
publisher Dove Medical Press
record_format MEDLINE/PubMed
spelling pubmed-48870442016-06-15 Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial Myers, Stephen P Mulder, Ann M Baker, Don G Robinson, Shelley R Rolfe, Margaret I Brooks, Lyndon Fitton, J Helen Biologics Original Research PURPOSE: Preliminary investigation of a fucoidan with demonstrated reduction in the symptoms of osteoarthritis (OA) of the hip and knee. PATIENTS AND METHODS: A double-blind randomized controlled trial was carried out to determine the safety and efficacy of a 300 mg dose of a Fucus vesiculosus extract (85% fucoidan) over a 12-week period in a population (n=122) with mild-to-moderate OA of the hip and knee as measured by the validated instrument “Comprehensive Osteoarthritis Test.” Safety was measured by assessing cholesterol, liver function, renal function, and hematopoietic function, and closely monitoring adverse events. RESULT: Ninety-six participants completed the study. The reduction in symptoms of OA was not significantly different from the placebo response. There were no changes in the blood measurements that were of any clinical significance during the course of the study. CONCLUSION: The F. vesiculosus fucoidan extract was safe and well tolerated. At a dose of 300 mg, the extract showed no difference in reduction of OA symptoms from the placebo. Dove Medical Press 2016-05-26 /pmc/articles/PMC4887044/ /pubmed/27307702 http://dx.doi.org/10.2147/BTT.S95165 Text en © 2016 Myers et al. This work is published and licensed by Dove Medical Press Limited The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution – Non Commercial (unported, v3.0) License (http://creativecommons.org/licenses/by-nc/3.0/). By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed.
spellingShingle Original Research
Myers, Stephen P
Mulder, Ann M
Baker, Don G
Robinson, Shelley R
Rolfe, Margaret I
Brooks, Lyndon
Fitton, J Helen
Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
title Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
title_full Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
title_fullStr Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
title_full_unstemmed Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
title_short Effects of fucoidan from Fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
title_sort effects of fucoidan from fucus vesiculosus in reducing symptoms of osteoarthritis: a randomized placebo-controlled trial
topic Original Research
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4887044/
https://www.ncbi.nlm.nih.gov/pubmed/27307702
http://dx.doi.org/10.2147/BTT.S95165
work_keys_str_mv AT myersstephenp effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial
AT mulderannm effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial
AT bakerdong effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial
AT robinsonshelleyr effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial
AT rolfemargareti effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial
AT brookslyndon effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial
AT fittonjhelen effectsoffucoidanfromfucusvesiculosusinreducingsymptomsofosteoarthritisarandomizedplacebocontrolledtrial